Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Menopause. 2014 Apr;21(4):403–409. doi: 10.1097/GME.0b013e31829d4c4c

Table 1.

Characteristics of the Study Population

Demographic Characteristics HIV + (N= 33) HIV − (N= 33) P-Value
  Age (years) 47 (45,48) 47 (46,49) 0.06
     % older than median split 33% (11) 45% (15) 0.31
  Race: %(#)
     Non-White 64% (21) 52% (17) 0.32
     Hispanic Ethnicity 15% (5) 12% (4) 0.72
  Body Mass Index 28.6±6.5 28.7±5.6 0.98
  Current Smoker % (#) 70% (23) 42% (14) 0.03*
  History of Substance Abuse % (#) 76% (25) 36% (12) 0.001**
  Current Methadone use % (#) 9% (3) 6% (2) 0.64
  Current selective serotonin reuptake inhibitor (SSRI) use % (#) 33% (11) 18% (6) 0.16

Menopause-Related Clinical Characteristics

  Total Number of Periods in the Past Year 5 (4,9) 6 (4,10) 0.53
  Experienced hot flashes 8 or more days in the past 4 weeks (range:0–28 days) 67% (22) 42% (14) 0.048*
  Follicle Stimulating Hormone (mIU/mL) †† 24 (8,53) 35 (15,63) 0.19
  Estradiol (pg/mL) ††† 60 (32, 206) 81 (44,154) 0.61
  (pmol/L) 220 (118,756) 297 (162,565)

HIV-Related Characteristics

  Duration of HIV (years) 14± 6 - -
  Currently taking Antiretroviral Therapy % (#) 91% (30) - -
       Current NRTI use 91% (30) - -
       Current NNRTI use 9% (3) - -
       Current PI use 45% (15) - -
  CD4 count (#/mm3)†††† 686±432 - -
  Nadir CD4 count (#/mm3)††††† 199 (60,290) - -

Data are reported as % (N) for categorical variables, and for continuous variables, as mean/SD or median (IQR=interquartile range) for data that were not normally distributed.

*

=P<0.05,

**

=P<0.01.

Median hot flash frequency split. Missing values are not included in the calculation: N=2,

†††

Missing values not included in calculation: N=3,

††††

Missing values not included in calculation: N=7,

†††††

Missing values not included in calculation: N=3. PI = protease inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor.